Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brady

Showing results (551-560 of 627) with videos related to

Pageof 63
Sort By:
Nature|August 31, 2017
Commensal bacteria make GPCR ligands that mimic human signalling moleculesLouis J Cohen, Daria Esterhazy, Seong-Hwan Kim, et al.
Molecular Cancer Therapeutics|December 14, 2002
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivoDeborah DeFeo-Jones, Stephen F Brady, Dong-Mei Feng, et al.
Journal of Medical Genetics|October 9, 2023
Genetic complexity of diagnostically unresolved Ehlers-Danlos syndromeAnthony M Vandersteen, Ruwan A Weerakkody, David A Parry, et al.
Current Oncology (Toronto, Ont.)|October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspectiveA M Oza, V Castonguay, D Tsoref, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
JAMA Oncology|January 1, 2016
Inherited Mutations in Women With Ovarian CarcinomaBarbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Gynecologic Oncology|February 1, 2011
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutationsRobin A Lacour, Shannon N Westin, Larissa A Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
The Journal of Urology|January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral areaM S Soloway, S Beckley, M F Brady, et al.
British Journal of Cancer|February 20, 2022
Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health serviceEamonn R Maher, Julian Adlard, Julian Barwell, et al.
Pageof 63

Showing results (551-560 of 627) with videos related to

Sort By:
Pageof 63
Nature|August 31, 2017
Commensal bacteria make GPCR ligands that mimic human signalling moleculesLouis J Cohen, Daria Esterhazy, Seong-Hwan Kim, et al.
Molecular Cancer Therapeutics|December 14, 2002
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivoDeborah DeFeo-Jones, Stephen F Brady, Dong-Mei Feng, et al.
Journal of Medical Genetics|October 9, 2023
Genetic complexity of diagnostically unresolved Ehlers-Danlos syndromeAnthony M Vandersteen, Ruwan A Weerakkody, David A Parry, et al.
Current Oncology (Toronto, Ont.)|October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspectiveA M Oza, V Castonguay, D Tsoref, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
JAMA Oncology|January 1, 2016
Inherited Mutations in Women With Ovarian CarcinomaBarbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Gynecologic Oncology|February 1, 2011
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutationsRobin A Lacour, Shannon N Westin, Larissa A Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
The Journal of Urology|January 1, 1983
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral areaM S Soloway, S Beckley, M F Brady, et al.
British Journal of Cancer|February 20, 2022
Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health serviceEamonn R Maher, Julian Adlard, Julian Barwell, et al.
Pageof 63